Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

2017108 citationsJournal Articlehybrid Open Access

Authors

Joyce O’Shaughnessy · Texas Oncology

Katarína Petráková · Masaryk Memorial Cancer Institute

Gabe S. Sonke · The Netherlands Cancer Institute

Pierfranco Conté · Istituti di Ricovero e Cura a Carattere Scientifico

Carlos L. Arteaga · Vanderbilt University Medical Center

David Cameron · Edinburgh Cancer Research

Lowell L. Hart

Abstract

Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.

Topics & Keywords

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Breast Cancer Research and Treatment

Volume 168, Issue 1, pp. 127-134

DOI: 10.1007/s10549-017-4518-8

Field-Weighted Citation Impact: 10.02